ARTICLE | Clinical News
GTI-2040: Began Phase II trial
November 5, 2001 8:00 AM UTC
Lorus Therapeutics Inc. (TSE:LOR; LORFF), Toronto, Ontario Product: GTI-2040 Business: Cancer Therapeutic category: Antisense, Cell proliferation Target: R2 subunit of ribonucleotide reductase Descr...